{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:58:03Z","timestamp":1773842283866,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.anndiagpath.2022.151981","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T02:05:36Z","timestamp":1653703536000},"page":"151981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma\/paraganglioma: A cohort study"],"prefix":"10.1016","volume":"60","author":[{"given":"Ling-Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-Chu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2022.151981_bb0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/his.13402","article-title":"Pathology and genetics of phaeochromocytoma and paraganglioma","volume":"72","author":"Turchini","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/gs.2019.10.25","article-title":"Pheochromocytoma\/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options","volume":"9","author":"Antonio","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7090242","article-title":"Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine","volume":"7","author":"Kimura","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00423-011-0850-3","article-title":"Malignant pheochromocytoma: new malignancy criteria","volume":"397","author":"de Wailly","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ando.2019.04.003","article-title":"Emerging molecular markers of metastatic pheochromocytomas and paragangliomas","volume":"80","author":"Goncalves","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0035","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0045","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.surg.2014.08.044","article-title":"Predictors of recurrence in pheochromocytoma","volume":"156","author":"Press","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00423-011-0850-3","article-title":"Malignant pheochromocytoma: new malignancy criteria","volume":"397","author":"de Wailly","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00432-007-0261-6","article-title":"A logistic regression model for predicting malignant pheochromocytomas","volume":"134","author":"Gao","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1365-2559.2003.01645.x","article-title":"Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas","volume":"43","author":"Salmenkivi","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168413","article-title":"Disentangling of malignancy from benign pheochromocytomas\/paragangliomas","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2796.2009.02111.x","article-title":"SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes","volume":"266","author":"Pasini","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/5584_2016_76","article-title":"Phaeochromocytoma and paraganglioma","volume":"956","author":"Gunawardane","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0090","first-page":"105","article-title":"Simultaneous occurrence of germline mutations of SDHB and TP53 in a patient with metastatic pheochromocytoma","author":"Gniado","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/156652413804486214","article-title":"Functions of S100 proteins","volume":"13","author":"Donato","year":"2013","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.anndiagpath.2022.151981_bb0100","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/0019-5154.135526","article-title":"S-100 immunostaining in the distinction of borderline tuberculoid leprosy from other cutaneous granulomas","volume":"59","author":"Tirumalae","year":"2014","journal-title":"Indian J Dermatol"},{"issue":"12(11)","key":"10.1016\/j.anndiagpath.2022.151981_bb0105","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"8","author":"Koh","year":"2017","journal-title":"PLoS One"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:34:17Z","timestamp":1761078857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913422000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":21,"alternative-id":["S1092913422000831"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151981","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma\/paraganglioma: A cohort study","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151981"}}